Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Canadian report of real-world outcomes in myeloma pts who reach 3rd-line therapy notes dara + len produced best responses, with mPFS of 25.6 months, while anti-CD38 + pom had mPFS of 6-9 months; median OS was 29.7 months.”
Title: Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Authors: Martha L. Louzada, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Engin Gul, Smriti Sharma, Richard LeBlanc
You can read the Full Article in Blood Neoplasia.
You can find other articles featuring Robert Orlowski on OncoDaily.
